- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.11. | SKINVISIBLE, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.10. | SKINVISIBLE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| SKINVISIBLE Aktie jetzt für 0€ handeln | |||||
| 03.10. | Skinvisible, Inc.: Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development | 243 | ACCESSWIRE | Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / October... ► Artikel lesen | |
| 15.08. | SKINVISIBLE, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.07. | Skinvisible Pharmaceuticals, Inc.: Promising Data on Transdermal Obesity Formulations Announced by Skinvisible | 343 | ACCESSWIRE | Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare TechnologyLAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Pharmaceuticals... ► Artikel lesen | |
| 24.06. | Skinvisible, Inc.: Skinvisible Expands Obesity Patent Application for Transdermal Delivery | 318 | ACCESSWIRE | Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an innovative... ► Artikel lesen | |
| 29.05. | Skinvisible meldet innovatives Adipositas-Patent für eine fortschrittliche transdermale Behandlung an | 364 | IR-WORLD | Verbesserte Verabreichung von GLP-1-Rezeptoragonisten und CB-1-Rezeptorantagonisten durch das topische / transdermale Verabreichungssystem
Invisicare
LAS VEGAS, NV / ACCESSWIRE... ► Artikel lesen | |
| 29.05. | Skinvisible, Inc.: Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment | 504 | ACCESSWIRE | Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Enhanced by Invisicare Topical / Transdermal Delivery System LAS VEGAS, NV / ACCESSWIRE / May 29, 2024 / Skinvisible Pharmaceuticals... ► Artikel lesen | |
| 14.02. | Skinvisible, Inc.: Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome | 433 | ACCESSWIRE | LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DIGICANN VENTURES | 0,004 | 0,00 % | CSE Bulletin: Halted for Fundamental Change - Digicann Ventures Inc. (DCNN) | le 30 septembre/September 2024
Trading in the shares of Digicann Ventures Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Change pursuant... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,002 | -33,33 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
| SINOPHARM | 2,662 | +0,87 % | Aktie der Sinopharm Group kann Vortagsniveau nicht halten (2,451 €) | Das Wertpapier der Sinopharm Group notiert heute ein wenig leichter. Die Aktie notiert zur Stunde bei 2,45 Euro. Die Sinopharm Group-Aktie verzeichnet derzeit einen Kursverlust von 1,11 Prozent. Sie... ► Artikel lesen | |
| INDIVA | 0,016 | 0,00 % | SNDL Inc.: SNDL Emerges as Canada's Leading Producer of Edibles with Indiva Acquisition | CALGARY, AB, Nov. 4, 2024 /CNW/ - SNDL Inc. (Nasdaq: SNDL) ("SNDL" or the "Company") announced today that, in the context of Indiva Limited's ("Indiva" and together... ► Artikel lesen | |
| CSPC PHARMA | 0,580 | -1,02 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYH2062 INJECTION (SIRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL | ||
| ORAMED PHARMACEUTICALS | 2,360 | -0,84 % | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt | NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery... ► Artikel lesen | |
| ADASTRA | 0,204 | +36,91 % | Adastra Holdings Ltd.: Adastra Holdings Announces Annual General Meeting | Langley, British Columbia--(Newsfile Corp. - December 10, 2024) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) ("Adastra" or the "Company"), a leader in cannabis processing and production, is pleased... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,930 | +1,43 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan | CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| LEEF BRANDS | 0,191 | +19,85 % | Leef Brands Inc (2): Leef closes $500,000 second tranche of placement | ||
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc: Molecule amends, settles, converts debentures | ||
| NUMINUS WELLNESS | 0,024 | +10,91 % | Numinus Wellness Inc.: Numinus Wellness Comments on FDA Decision on New Drug Application for MDMA-Assisted Therapy for PTSD | VANCOUVER, BC, Aug. 12, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a leader in mental health care specializing in innovative and evidence-based... ► Artikel lesen | |
| ROCKET LAB USA | 28,440 | 0,00 % | Spotlight on Rocket Lab USA: Analyzing the Surge in Options Activity | ||
| VERTEX PHARMACEUTICALS | 410,60 | 0,00 % | Vertex Pharmaceuticals Incorporated: Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 | Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference... ► Artikel lesen | |
| VIATRIS | 12,560 | 0,00 % | Viatris Stock: Is VTRS Outperforming the Healthcare Sector? | ||
| PFIZER | 26,565 | 0,00 % | Novo Nordisk speckt ab, Gerresheimer verliert ebenfalls an Wert, Eli Lilly frohlockt und auch bei Pfizer herrscht gute Laune | Noch vor Jahresende wollte Novo Nordisk neue Studiendaten zum in Entwicklung befindlichen Abnehmmedikament CagriSema vorstellen. Dieses Versprechen konnte das Unternehmen auch einlösen. Am Freitag erhielten... ► Artikel lesen |
SKINVISIBLE INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SKINVISIBLE INC finden Sie auf Wallstreet Online.
